Literature DB >> 18656619

672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.

Nicholas C Wisnoski1, Courtney M Townsend, William H Nealon, Jean L Freeman, Taylor S Riall.   

Abstract

BACKGROUND: Acinar cell carcinoma (ACC) is a rare cancer of the pancreas accounting for approximately 1% of nonendocrine tumors. Because no large series of patients with ACC exist, our understanding of this disease comes mainly from small retrospective reports and anecdotal experience.
OBJECTIVE: Our goal was to evaluate a large population-based cohort of patients with ACC and compare their demographic factors and outcomes to those of patients with pancreatic adenocarcinoma (PA).
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database (1988 to 2003), we identified all patients with ACC or PA. The demographic factors, tumor characteristics, resection status, and long-term survival were compared between the 2 groups.
RESULTS: A total of 672 patients with ACC and 58,526 with PA were identified. The mean age at the time of diagnosis was significantly lower for ACC than PA (56 years vs 70 years, P < .001). Compared with patients with PA, patients with ACC were more likely to be male (54% vs 48%, P = .007) and white (85% vs 81%, P = .03). Based on SEER clinical staging, patients with ACC were less likely to have unstaged disease (8% vs 18%). Of the 616 patients with staged ACC, 16% had localized disease, 26% had regional disease, and 58% had distant disease. In the 47,896 staged patients with PA, 10% had localized disease, 33% had regional disease, and 57% had distant disease (P < .0001 compared to ACC). Based on clinical extent of disease, 81% of patients with locoregional ACC and 70% of patients with locoregional PA were resectable. However, only 69% of ACC patients with locoregional disease and 27% of PA patients with locoregional disease underwent surgical resection. The overall 5-year survival was 42.8% for ACC (median, 47 months) and 3.8% for PA (median, 4 months, P < .0001). Patients with unresected ACC had a 5-year survival rate of 22% compared to 2% in patients with unresected PA (P < .0001). Surgical resection significantly improved survival. The 5-year survival was 72% in resected ACC and 16.3% in resected PA (P < .0001). Multivariate Cox proportional hazards regression model results suggested patients with ACC were less likely to die (hazard ratio = 0.241; 95% confidence interval, 0.22-0.27) than patients with PA after controlling for gender, race, stage, SEER region of diagnosis, and surgical resection status.
CONCLUSIONS: Consistent with anecdotal reports and previous retrospective studies, ACC is a more indolent disease than PA. Patients with ACC tend to present at a younger age, are more likely to have resectable disease, and are much more likely to undergo potentially curative resection. The long-term survival for patients with ACC is significantly better when compared to the long-term survival of patients with PA.

Entities:  

Mesh:

Year:  2008        PMID: 18656619     DOI: 10.1016/j.surg.2008.03.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  66 in total

1.  Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease.

Authors:  Jennifer L Lund; Linda C Harlan; K Robin Yabroff; Joan L Warren
Journal:  Cancer Invest       Date:  2010-08       Impact factor: 2.176

Review 2.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Mixed acinar-endocrine carcinoma of the pancreas with intraductal growth into the main pancreatic duct: Report of a case.

Authors:  Shinjiro Kobayashi; Takeshi Asakura; Nobuyuki Ohike; Takeharu Enomoto; Joe Sakurai; Satoshi Koizumi; Taiji Watanabe; Hiroshi Nakano; Takehito Otsubo
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

4.  Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Authors:  Emmet J Jordan; Olca Basturk; Jinru Shia; David S Klimstra; William Alago; Michael I D'Angelica; Ghassan K Abou-Alfa; Eileen M O'Reilly; Maeve A Lowery
Journal:  J Gastrointest Oncol       Date:  2017-10

5.  Mixed acinar-endocrine carcinoma of the pancreas treated with S-1.

Authors:  Yusuke Kanemasa; Terumi Kamisawa; Taku Tabata; Sawako Kuruma; Susumu Iwasaki; Kazuro Chiba; Go Kuwata; Takashi Fujiwara; Hideto Egashira; Koichi Koizumi; Junko Fujiwara; Takeo Arakawa; Kumiko Momma; Hirofumi Rokutan; Shinichiro Horiguchi; Tsunekazu Hishima
Journal:  Clin J Gastroenterol       Date:  2013-09-05

6.  c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers.

Authors:  Stefano La Rosa; Barbara Bernasconi; Alessandro Vanoli; Amedeo Sciarra; Kenji Notohara; Luca Albarello; Selenia Casnedi; Paola Billo; Lizhi Zhang; Maria Grazia Tibiletti; Fausto Sessa
Journal:  Virchows Arch       Date:  2018-05-02       Impact factor: 4.064

7.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

8.  Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.

Authors:  Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-14       Impact factor: 4.553

9.  Pancreatic acinar cell carcinoma: a multi-institutional study.

Authors:  Jesus M Matos; C Max Schmidt; Olivier Turrini; Narasimhan P Agaram; Marco Niedergethmann; Hans Detlev Saeger; Nipun Merchant; Cynthia S Johnson; Keith D Lillemoe; Robert Grützmann
Journal:  J Gastrointest Surg       Date:  2009-06-03       Impact factor: 3.452

10.  Clinical and CT imaging features of pancreatic acinar cell carcinoma.

Authors:  Shengping Hu; Shudong Hu; Mingliang Wang; Zhiyuan Wu; Fei Miao
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.